CUV
Clinuvel Pharmaceuticals Ltd
Biotechnology
·
Healthcare
6
comments
2
fund managers
past 90 days
About Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Ltd. is a Melbourne-based biopharmaceutical company founded in 1999. The firm specializes in developing innovative treatments for rare skin disorders. Its primary product is SCENESSE, a proprietary photoprotective drug designed to address specific dermatological conditions. Clinuvel focuses on the clinical development and commercialization of pharmaceutical solutions for individuals suffering from light-related skin ailments. As a research-driven enterprise, the company continues to manage its drug pipeline and global distribution from its Australian headquarters.
Commentary Volume
6
Comments
2
Fund managers
0
Past 90 days
SOURCE
ACTION
COMMENT PREVIEW
FUND MANAGER
DATE
Loading...
.
​Loading...
Loading...
Loading...
Loading...
Source: Ipsum Capital Q4 Quarterly Letter · Published 14 March 2025
Report a problem
Loading...
.
Loading...
Loading...
Loading...
Loading...
§ Important Notice
The entries below are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Commentary
Sector
Healthcare
Market cap
$451M
Fund managers
2 managers
First covered
31 Dec 2023
Last updated
31 Mar 2026
Company Details
Related Themes
ic
Ipsum Capital
6 comments
ic
Amet Funds
4 comments
ic
Dolor
3 comments
Top Investors Covering MIN
§ Reminder
The entries above are records originating from third-party statements. Thesis Tracker does not rank, recommend or endorse any fund manager, fund or security. Investment decisions should be made on the basis of the relevant Product Disclosure Statement and, where appropriate, advice from a licensed adviser.
Frequently asked questions about Clinuvel Pharmaceuticals Ltd (ASX:CUV)
Frequently asked questions
Who is investing in Clinuvel Pharmaceuticals Ltd (ASX:CUV)?
Fund managers including Jencay Capital and Elston Asset Management have invested in Clinuvel Pharmaceuticals Ltd (ASX:CUV).
What is the short interest in Clinuvel Pharmaceuticals Ltd (ASX:CUV)?
The short interest in Clinuvel Pharmaceuticals Ltd (ASX:CUV) is 6.60% which makes it the 29th most shorted stock on the ASX. Of the 50.2M shares that Clinuvel Pharmaceuticals Ltd has on issue, 3.3M have been sold short.
What does Clinuvel Pharmaceuticals Ltd (ASX:CUV) do?
Clinuvel Pharmaceuticals Ltd. is a Melbourne-based biopharmaceutical company founded in 1999. The firm specializes in developing innovative treatments for rare skin disorders. Its primary product is SCENESSE, a proprietary photoprotective drug designed to address specific dermatological conditions. Clinuvel focuses on the clinical development and commercialization of pharmaceutical solutions for individuals suffering from light-related skin ailments. As a research-driven enterprise, the company continues to manage its drug pipeline and global distribution from its Australian headquarters.
Loading...